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Localization of Metastases from Medullary Thyroid Carcinoma Using
Different Methods
Rosa C. Cabezas,* Luis Berna,* Montserrat Estorch,* Ignacio Carrio,' and Angeles
Garcia-Ameijeiras*

We analyzed the efficiency of three different noninvasive methods in the localization of recurrent
medullary thyroid carcinoma (MTC). Nine patients (six females and three males) with biochemical
evidence of disease afler primary surgery were subjected to
anti-carcinoembryonic antigen (antiCEA) antibody,
meta-iodo-benzylguanidine (MIBG), and computed tomography. Another female
patient, in biochemical remission for six years after initial surgery, was also studied using the same
methods. Three of the ten patients had negative results with all three methods (including the patient in
remission). The other seven patients showed abnormal uptake of labeled anti-CEA antibody in various
localizations: only two of these patients had a corresponding pathological image hy computed
tomography and only one by "'/ MIBG. These preliminary results suggest thatanti-CEA
scanning
may be the most sensitive noninvasive method for the localization of MTC recurrences. (Henry Ford
Hosp MedJ 1989:37:169-72)

M

edullary thyroid carcinoma (MTC) patients, both hereditary and sporadic, often have clinical and biochemical evidence of disease recunence after primary surgery (1-3). Since
surgery is the effective therapy for the disease (4-6) (either primary or secondary), localization ofthe cancer tissue and its dissemination is of primary importance.
Several localization methods have been used, from conventional plain chest roentgenograms to computed tomography and
" ' I meta-iodo-benzylguanidine (MIBG) scans, with variable
degrees of efficiency (7-13). Some authors have also advocated
the use of invasive techniques, such as venous catheterization,
but this limits the areas studied and hence metastases in unsuspected organs may be missed (14).
Since all forms of MTC are known to express and secrete carcinoembryonic antigen (CEA) (15,16) and labeled monoclonal
antibodies against it have been developed for human scintiscanning, we studied the ability of such an antibody to detect the
presence of recurrent MTC and compared the results with those
obtained in the same patients using '^'1 MIBG and computed tomography as the means of detection. Previous studies (17,18)
have shown that '^^'I anti-CEA antibodies were u.seful for the detection of MTC, although the number of patients studied was
small.

a sternotomy a few months before the tests were performed.
Case 9's MTC was diagnosed by family screening; she had ' " I
anti-CEA scanning prior to surgery. On physical examination
the thyroid gland was considered normal. Bilateral microscopic
foci of MTC, with positive immunostaining for CEA, were
found in the thyroid. Two patients (cases 6 and 8) had extemal
neck radiation after initial surgery. Calcitonin (CT) was elevated
in all patients except case 10, and five patients had high tevels of
CEA. Three patients had hereditary MTC, whereas the other six
had an apparently sporadic form of MTC. None was diagnosed
as having multiple endocrine neoplasia type 2,

Materials and Methods
CT measurements were performed by radioimmunoassay
using a commercial kit (Calcitonin II RIA, tncstar Corporation,
Stillwater, MN). CT stimulation tests were performed as described previously (19). For the '^'t anti-CEA and the '^'I MIBG
scans, the patients had thyroid remnant blockage with Lugot
drops for a total of nine days, starting two days prior to the injection of the labeled compound. Potassium perchlorate (I g orally)
was administered two hours prior to the injection and every 12

Patients
The patients' data are summarized in Table 1. We studied ten
patients, seven females and three mates, with mean ages of
42.14 ± 11.79 years and 46.33 ± 3.05 years, respectivety. The
follow-up period averaged 7.19 ± 4.09 years. Atl patients except case 9 had neck surgery for MTC; one ofthese patients had
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Table I
Descriptive Data of All Patients

Table 2
Results of MTC Localization Techniques

Poststiraulatory
Age al
Diagnosis

CTPeak

Sex

Basal CT
(pg/raL)

M
F
M
M
f
F
F
F
F
F

280
300
>500
> 10.000
689
3 l.s
4,SI
311
63
Undetectable

915
868
9,954

Coraputed

Anti-CEA

Tomography

MIBG

Surgery

Normal
Normal
-1- BM
4- Neck
BM
Normal
Normal
Normal
-1- (subpleural
L Nodule)

Normal
Normal
Not Done
Normal

Not Done
Not Done

5
6
7
8

-1- LM
Norraal
4- BM
3- Neck
BM
J- Neck
-1- Neck
3- LM
Norraal

Not Done
Not Done
Not Done
Not Done

Normal CT levels are « IOO pg/mL for males and s 45 to 50 pg/mL for females. Nonnal
ptiststimulatory CT levels are s 500 pg/mL for males and ss 200 pg/mL for females.
Normal CEA is < 5 jig/L.

9
10

4- Neck
Normal

Not Done
Normal

Norraal
3- Neck
Norraal
+ (R
paracardiac
uptake)
Not Done
Norraal

hours (250 mg) for seven days thereafter The '^'I anti-CEA
scans were performed with 1 mg of the F(ab')2 fraction of antiCEA monoclonal antibody (Sorin, Biomedica, Italy) injected
intravenously, Whote body planar scans were taken at two, five,
and seven days postinjection in anterior and posterior projections, using a conventional targe field of view camera with a
high energy collimator, 20% w centered on a 360 Kev peak.
Analog and digital images of 500 K counts each collected on a
128 X 128 matrix were stored for subsequent analysis.
Within 15 days of the '^'I anti-CEA scan, and using a similar
procedure, whole body planar scans at 24, 48, and 72 hours
after intravenous administration of I mCi of " ' I MIBG were obtained in eight patients.
Cervical, thoracic, and abdominal computed tomography
scans were perfonned in nine patients on a Siemens Somaton
whole body scanner, operating at 125 Kvp and 230 mAs, with a
5 second scan time and at 8 mm slice thickness.

subpleural nodule detected by computed tomography which was
not considered tumoral.
None of the patients had any adverse reactions to the administered radiolabeled compounds.

Case
1

:
3
4
5
6
7
8
9
10

49
5.^
43
47
4(.
47
32
22
40

(pg/iiiL)

—
—
—
852

—
500
Undetectable

CEA
P-g/L
<2.5
5.85
94.25
6.6
11.15
1
30.72
2.85
2.5
<2.5

Results
"'I anti-CEA
Best results were obtained in the studies performed seven
days after the intravenous injection. Case 10, who had been in
biochemical remission for six years, had a normal scintiscan,
whereas seven of nine patients with active disease had pathological uptake (Table 2). One such abnormal scan is shown in Fig 1.
Three patients had abnormal uptake in the cervical area, one in
the bilateral superior mediastinum and low cervical bed, one bilaterally in the mediastinum, and two in the left mediastinum
(Fig 2). These results are summarized in Table 2. Case 3 had the
tests performed on two occasions within ten months, and the results were identical on alt occasions.
i^'I MIBG
Only two of the eight patients studied had abnormal uptakes:
one patient had a positive uptake in the cervical area, which was
also observed in the " ' I anti-CEA study, and the other patient
had an abnormal right paracardiac uptake which in subsequent
reviews was thought to be an artifact. This patient atso had a left
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Case
1
2
3
4

(+)
(+)

(+)

—

R = right. L = left, B = bilateral, and M = media.stinum.

Computed tomography
Two of nine patients who had computed tomography scans
had pathological images compatible with metastases in the paratracheat and infraclavicular nodes. Both had abnormal ' " I antiCEA uptake in the same areas.
Other data
Three of seven patients with abnormal '-"I anti-CEA uptake
have had surgery. Immunohistochemical anatysis of the resected
tissues confirmed the presence of MTC in each. Complete normalization of the CT and CEA levels was observed after surgery
in only one of these three patients; one patient is awaiting right
thoracotomy and the other has had a decrease of the CT levels
postoperatively. One patient has refused surgery or any other invasive procedure, and another prefened extemal radiation when
offered by a physician from another institufion. The other remaining patients are awaiting surgery.

Discussion
Early detection of recunent MTC is of primary importance
since the patients' prognosis invariably worsens with the advance of the disease (15,19,20), which is partly due to the lack of
effective therapy other than surgery (21,22). It is important to
realize that between 50% and 70% of MTC patients already have
metastases at the time of diagnosis and that approximately 50%
will develop them thereafter (2-4).
Detection of primary and recurrent disease is now possible
through the determinations of basal and/or poststimulatory levels of CT (1,2,19). High postoperative levels of CT are considered clear evidence of persistence of the disease, especially
when an exaggerated response to the conventional secretagogues (either pentagastrin alone or pentagastrin combined
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Fig 1—Anterior view ofa "'I anti-CEA scan showing uptake in
a local neck recurrence 11 years after surgery.

with calcium) is observed. In our experience, high basal or
poststimulatory levets of CT after surgery (in seram obtained as
earty as one week after initial thyroidectomy) were always followed by increasing CT tevels in the subsequent determinations,
which strongly suggests persistence of disease.
Although diagnosis of disease persistence is cunently possible, localization of the metastases and, possibly more important, determination of the extent of the disease have proved to be
difficult in many cases. Previous reports have suggested that " ' I
MIBG is a useful toot for detecfion of MTC (7-13). However,
others have found poor sensitivity of the technique (18). In our
study (Tabte 2), onty one of eight patients had an abnormal '^'I
MIBG uptake (case 8's resutts proved to be false-negative). Two
patients had the test performed on more than one occasion
within a two-year period with identical results.
Eight of nine patients with biochemical evidence of active
MTC had computed tomography scans performed (some on
multiple occasions), but tumor localization was possible in onty
two of these patients. Since our computed tomography studies
were performed at 8 mm cuts, smaller metastases may have been
missed; two of our patients had muttiple nodes that were not detected by this technique, presumably because of their small size,
tdentification of normal neck stractures can be difficult in cervical computed tomography scanning after certain types of procedures are done.
In OIU- study " ' I anti-CEA F(ab')2 antibody fragment proved
to be the most sensitive technique. Although only a small
number of patients were studied and we lack histologic proof in
all cases, our results suggest that this technique may be valuabte
in the localization of MTC sites. In case 9, who has normal CEA
values and the hereditary type of MTC diagnosed by famity
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Fig 2—anti-CEA
mediastinal nodes.

scan (posterior view) showing uptake in

screening, the '^'I anti-CEA uptake was posifive onty in the cervical area. No macroscopic thyroid nodules were seen at thyroidectomy. Her CT levels remained undetectable
postoperatively. Results in this patient indicate that even microscopic MTC can be detected by " ' I anri-CEA scanning. It could
be argued that the remaining normal thyroid had accumulated
free " ' I . However, the administration of '^'I blocking agents
prior to and during the seven days of the test would have prevented the uptake by the nonnal thyroid. We have used the same
procedure as that used in gastrointestinal cancer patients whose
thyroid glands are intact and in whom free '^'t thyroid uptake is
not seen.
Case to, who was in biochemical and clinical remission for
six years, had a negative '^'I anti-CEA uptake. Although this
may indicate that the test is reliabte with respect to negative resutts, the tack of uptake in cases 2 and 8 (both with moderately
elevated CT levels) refutes this assumption. Whether the pafients who showed uptake in some areas did not have other, as yet
undetected, metastases remains to be seen. Of the three patients
operated on, one stilt shows inexplicably high CT levels, although the '^'I anti-CEA resutts are negative. No false-positive
results for this test have been found. Since not atl patients have
had surgery, no firm conctusion can yet be made.
Although we have not observed any adverse reactions in the
patients studied, this possibility cannot be excluded. Since the
test may be repeated several times, it is possible that some patients may develop blocking anti-idiotypic antibodies against
the F(ab'), anti-CEA fragment rendering it inactive.
Our resutts suggest that, of the ttiree techniques studied, " ' I
anti-CEA screening is the most sensitive and promising technique, although studies in larger patient populations are needed.
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